Literature DB >> 17316156

Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course.

Melissa Lewis1, Jarrett R Amsden.   

Abstract

West Nile virus can cause a febrile illness that may progress to meningoencephalitis. The only available treatments are ribavirin (although it has had limited success in humans) and interferon alpha-2b. A small pilot study showed that starting treatment with interferon alpha-2b on days 1-4 of hospital admission may reduce disease severity and complications. We encountered an 83-year-old man with West Nile meningoencephalitis who began taking interferon alpha-2b 3 weeks after disease presentation. Although studies and reports indicate that treatment is less likely to provide a favorable response if administered after days 1-6 of the disease course, the patient experienced substantial beneficial effects from this treatment. This is the first case report, to our knowledge, that describes successful treatment with interferon alpha-2b after several weeks of West Nile virus infection. Further studies are warranted to more fully understand the value of interferon alpha-2b in treating West Nile meningoencephalitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17316156     DOI: 10.1592/phco.27.3.455

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  13 in total

1.  Arenaviruses and West Nile Virus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

Authors:  Judith A Anesi; Fernanda P Silveira
Journal:  Clin Transplant       Date:  2019-05-23       Impact factor: 2.863

2.  Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model.

Authors:  Justin G Julander; Jane Ennis; Jeffrey Turner; John D Morrey
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

Review 3.  Progress on the development of therapeutics against West Nile virus.

Authors:  Michael S Diamond
Journal:  Antiviral Res       Date:  2009-06-06       Impact factor: 5.970

Review 4.  Donor-derived West Nile virus infection in solid organ transplant recipients: report of four additional cases and review of clinical, diagnostic, and therapeutic features.

Authors:  Drew J Winston; Holenarasipur R Vikram; Ingrid B Rabe; Gundeep Dhillon; David Mulligan; Johnny C Hong; Ronald W Busuttil; Marek J Nowicki; Thomas Mone; Rachel Civen; Selam A Tecle; Kavita K Trivedi; Susan N Hocevar
Journal:  Transplantation       Date:  2014-05-15       Impact factor: 4.939

5.  Protection against West Nile virus infection in mice after inoculation with type I interferon-inducing RNA transcripts.

Authors:  Miguel Rodríguez-Pulido; Miguel A Martín-Acebes; Estela Escribano-Romero; Ana-Belén Blázquez; Francisco Sobrino; Belén Borrego; Margarita Sáiz; Juan-Carlos Saiz
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

6.  Equine Immunoglobulin and Equine Neutralizing F(ab')₂ Protect Mice from West Nile Virus Infection.

Authors:  Jiannan Cui; Yongkun Zhao; Hualei Wang; Boning Qiu; Zengguo Cao; Qian Li; Yanbo Zhang; Feihu Yan; Hongli Jin; Tiecheng Wang; Weiyang Sun; Na Feng; Yuwei Gao; Jing Sun; Yanqun Wang; Stanley Perlman; Jincun Zhao; Songtao Yang; Xianzhu Xia
Journal:  Viruses       Date:  2016-12-18       Impact factor: 5.048

Review 7.  Interferons and their use in persistent viral infections.

Authors:  Stéphane Chevaliez; Jean-Michel Pawlotsky
Journal:  Handb Exp Pharmacol       Date:  2009

8.  Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man.

Authors:  Jean K Lim; Andrea Lisco; David H McDermott; Linda Huynh; Jerrold M Ward; Bernard Johnson; Hope Johnson; John Pape; Gregory A Foster; David Krysztof; Dean Follmann; Susan L Stramer; Leonid B Margolis; Philip M Murphy
Journal:  PLoS Pathog       Date:  2009-02-27       Impact factor: 6.823

Review 9.  A review of the epidemiological and clinical aspects of West Nile virus.

Authors:  Timothy J Gray; Cameron E Webb
Journal:  Int J Gen Med       Date:  2014-04-11

10.  Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71.

Authors:  Cheng-Wen Lin; Chia-Fang Wu; Nai-Wan Hsiao; Ching-Yao Chang; Shih-Wein Li; Lei Wan; Ying-Ju Lin; Wei-Yong Lin
Journal:  Int J Antimicrob Agents       Date:  2008-08-13       Impact factor: 5.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.